Biotechnology, which received funding from the U.S. Operation Warp Speed program, also said it has around $ 400 million in customer deposits for a potential supply of its mRNA-1273 vaccine.
Moderna made the announcement in its earnings release Wednesday morning. The company recorded a loss that was lower than expected, but revenue higher than expected.
Actions of Modern ( has fallen by around 2% on the news, but stock has climbed more than 300% this year in hopes of developing a successful coronavirus vaccine. The company has also come under close scrutiny by some investors, as several insiders have sold shares as they’ve taken off. )
People have also been watching closely to see what drug companies plan to charge for post-biotech treatments. Sciences of Gilead ( revealed in June that its drug remdesivir would cost $ 520 a vial, or $ 3,120 for a five-day six-vial course, for people covered by private health insurance plans. )
Moderna is just one of many companies trying to design a vaccine. Actions of another small biotechnology, Novavax (, climbed 20% on Wednesday after announcing its own promising clinical trial results. )
Novavax has also received funding for Operation Warp Speed, as have giant pharmaceutical companies Johnson & Johnson (, )AstraZeneca (, )GlaxoSmithKline ( and a joint trial by giant Big Pharma )Pfizer ( and Germany )BioNTech (. )